The oncologist-executive at the $6.6 billion biomed firm helped get four FDA approvals this year, including one for Avastin, a drug designed for use by chemotherapy patients with colon or rectal cancer. Her ambitious goal: to bring at least 15 major new drugs to market by 2010.